Vascular and stroma normalization can be achieved by combining anti-VEGF treatment with stroma normalizing agents [e.g., Losartan (52) and Ketotifen (53)] to precondition the tumor microenvironment prior to therapy. This evidence concerns the gene VEGFA and neoplasm.